Benefits and costs of new Alzheimer's drugs for Black and low‑income communities
Effectiveness and Cost-effectiveness in Alzheimer’s Treatment
This project looks at how new anti‑amyloid Alzheimer's medicines work in real life and what they cost for people, especially Black and low‑income adults with mild cognitive problems or Alzheimer's.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Michigan at Ann Arbor NIH-funded |
| Lab location | 1 site (Ann Arbor, United States) |
| Project ID | NIH-11337252 on NIH RePORTER |
What this research studies
You would be invited to interviews and surveys in Flint, Michigan if you have mild cognitive impairment or Alzheimer's to talk about diagnosis, monitoring, getting treatment, transportation, and out‑of‑pocket costs. Researchers will engage local stakeholders and build a plan for future analyses to make sure the work reflects community priorities. The team will also use real‑world healthcare data to measure how often people use anti‑amyloid drugs, how well they stick to treatment, the costs involved, and any adverse events. The overall approach combines personal stories with health data to understand practical barriers and outcomes in groups that have been underrepresented.
Who could benefit from this research
Good fit: Ideal participants are adults with mild cognitive impairment or Alzheimer's disease, especially Black or low‑income individuals in Flint, Michigan and nearby communities.
Not a fit: People without cognitive impairment, those living outside the study area, or those not considering Alzheimer's treatment are unlikely to benefit directly from this work.
Why it matters
Potential benefit: If successful, the findings could help make Alzheimer's treatments safer, more affordable, and more accessible for Black and low‑income patients.
How similar studies have performed: Clinical trials have shown anti‑amyloid drugs can clear brain amyloid and provide some clinical benefit, but real‑world safety, cost, and effectiveness data for Black and low‑income groups remain limited.
Where this research is happening
Ann Arbor, United States
- University of Michigan at Ann Arbor — Ann Arbor, United States (Active)
Researchers
- Principal investigator: Callaghan, Brian Christopher — University of Michigan at Ann Arbor
- Study coordinator: Callaghan, Brian Christopher
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.